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The skin provides the first line defense of the human body against injury and infection. By integrating recent
findings in cutaneous immunology with fundamental concepts of skin biology, we portray the skin as a multi-
tasking organ ensuring body homeostasis. Crosstalk between the skin and its microbial environment is also
highlighted as influencing the response to injury, infection, and autoimmunity. The importance of the skin
immune network is emphasized by the identification of several skin-resident cell subsets, eachwith its unique
functions. Lessons learned from targeted therapy in inflammatory skin conditions, such as psoriasis, provide
further insights into skin immune function. Finally, we look at the skin as an interacting network of immune
signaling pathways exemplified by the development of a disease interactome for psoriasis.Introduction
The skin, with its surface area of 1.8 m2, is one of the largest
organs in the human body and most exposed surface to the
environment. Being constantly exposed to potential hazards
requires the skin to perform numerous tasks in order to maintain
homeostasis critical for health. Among other classical nonim-
mune functions, the skin provides a physical and biochemical
barrier and a sensory-receptive area; it ensures adequate hydra-
tion; and it allows synthesis of vitamins and hormones. The skin
is also required to serve as an immuno-protective organ that
actively defends deeper body tissues. Similar to lung and gut
mucosal barriers, the skin exploits the immune surveillance
versatility of a well-coordinated system of epithelial and immune
cells. Collectively, they ensure adequate immune responses
against trauma, toxins, and infections, while maintaining self-
tolerance, preventing allergy, and inhibiting autoimmunity. Long
gone are the days when the skin was considered a mere passive
barrier. This review portrays the skin as amultitasking organ, and
by integrating recent exciting findings, from both clinical and
murine models with fundamental concepts, we highlight how
skin immune functions contribute to human health.
Anatomy of the Skin
The unique ability of the skin to carry out multiple and wide-
ranging roles is very closely related to its structure, which is
composed of an outer epidermis overlying an inner dermis,
separated by a basement membrane. From the lowermost layer
to the uppermost visible part of the epidermis is the stratum
basale, the stratum spinosum, the stratum granulosum, and
the stratum corneum, the latter consisting of dead keratinocytes
called corneocytes. The physical and biochemical skin barrier
results from the combination of terminally differentiated epi-
dermal keratinocytes (KCs) and the acidic, hydrolipidic nature
of the skin, as a result of sweat, sebum, lipids, and antimicrobial
peptides (AMPs). Changes in lipid composition and epidermal
differentiation lead to a disturbed skin barrier, which plays
a role in the pathogenesis of several immune-mediated skinpathologies, such as atopic dermatitis and ichthyosis vulgaris
(Palmer et al., 2006; Smith et al., 2006). The epidermis is host
not only to KCs, but also to melanocytes and immune cells
such as Langerhans cells (LCs) and T lymphocytes. In addition,
it hosts nerve-ending cells (Merkel cells), essential for light-touch
and discrimination of shapes and texture. The dermis is
composed of an upper papillary (stratum papillare) and lower
reticular (stratum reticulare) dermis containing thin and thick
collagen fibers, respectively. The collagen fibers offer a mechan-
ical barrier as well as a structural framework in which to host
blood vessels and many immune cells such as dermal dendritic
cells (DDCs), ab T cells, gd T cells, natural killer (NK) cells, B cells,
mast cells, and macrophages.
At this point it is important to highlight that anatomical and
immunological differences exist between murine and human
skin (Gudjonsson et al., 2007), in order to better appreciate
information gleaned frommurinemodels of skin infection, inflam-
mation, and wounding. Mouse skin is covered by a thick layer of
fur, whereas human skin has sparse hair coverage. Hair aids in
waterproofing and prevention of desiccation and protects from
certain fungal infections. Mouse skin is also much thinner than
human skin with a faster epidermal cell turnover, resulting in
fast healing of wounds. Murine skin also contains a thin superfi-
cial muscle layer, the panniculus carnosus, which allows for
wound healing by contraction, leaving no scar upon healing,
whereas human skin heals via re-epithelialization and granula-
tion tissue formation, which can lead to scar formation. Immuno-
logical differences include the existence of subtypes of DCs not
present or not yet identified in humans such as CD207(langerin)+
CD103+ dermal DCs (DDCs). Whether analogous cell types exist
in human skin is currently being investigated. Moreover, mice,
but not humans, possess Vg5Vd1 T cells, named dendritic
epidermal T cells (DETCs), for their morphology and location.
Uniquely seeded to the basal epidermis during fetal develop-
ment, DETCs constitute more than 90% of epidermal T cells,
forming an interdigitating network with keratinocytes and over-
laying LCs. Human epidermal Vd1 (Toulon et al., 2009) andImmunity 35, December 23, 2011 ª2011 Elsevier Inc. 857
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attributed some of the functions exerted by DETCs in mice and
will be discussed later.
The skin is not a sterile place and as many as 1012 resident
bacteria/m2 are sheltered and prosper in the intercorneocytic
spaces. They feed on corneocyte debris and sebum and prevent
other undesirable bacteria from developing. The skin micro-
biome is dependent on the site that is being considered and on
sebum and moisture availability. A great step forward in helping
us to understand how and why the skin responds to microbes in
the way it does has been made by the establishment of the
Human Microbiome Project and in particular the skin micro-
biome (Grice and Segre, 2011). Three species of bacteria are
particularly well adapted to withstand the acidic pH environment
and host AMPs: Staphylococcus, Propionibacterium, and Cory-
nebacterium. Commensal bacteria like Staphylococcus epider-
midis appear to act as an additional barrier against colonization
of potentially pathogenic microbes and against the overgrowth
of already present opportunistic pathogens, by producing their
own AMPs to enhance host AMPs. They are also beneficial in
maintaining inflammatory homeostasis by suppressing excess
cytokine release after minor epidermal injury. Propionibacterium
acnes has maintained a controversial link with the pathogenesis
of acne in the face of being a skin-resident bacterium. Propioni-
bacterium species was found to be more extensively located on
the back of four subjects in the healthy skin group than in the
nose and feet (Grice and Segre, 2011), again supporting clinical
findings that acne is prone to occur on the backs of many
patients. More advanced technologies (e.g., whole genome
shotgun sequencing), able to differentiate between living and
dead bacteria, will soon provide further details regarding tempo-
rary and long-term skin-resident bacteria to identify the true
genetic diversity of the skin microflora (Grice and Segre, 2011).
Skin as an Immunocompetent Organ and a Window
into Tissue-Specific Immune Responses
Although skin nonimmune functions have been long known, its
immune function was not formally recognized until 1978, when
Streilein coined the term skin-associated lymphoid tissue
(SALT) to describe the continuous trafficking of immune cells
between the skin, draining lymph nodes (LNs), and the peripheral
circulation (Streilein, 1983). Expansion of this innovative concept
to include the vast majority of the cutaneous cellular com-
ponents led to the term skin immune system (SIS) (Bos and
Kapsenberg, 1986). Eventually, a detailed analysis of the dermal
compartment gave rise to the dermal immune system (DIS)
model in which dermal cells are crucially involved in the majority
of chronic inflammatory skin disorders (Nickoloff, 1993). More
recently, we have proposed a sentinel role in health and disease
for a spectrum of skin-resident cells (Nestle et al., 2009a), with
KCs involved in sensing pathogens and danger signals, migra-
tory DCs capable of initiating a diverse range of immune re-
sponses, and tissue-resident memory T (Trm) cells performing
crucial effector functions.
Analysis of clinical specimens and animal models of skin
inflammation and infection have contributed to the definition of
Trm cells as critical components of organ-based immunity (Fig-
ure 1; Sheridan and Lefranc¸ois, 2011; Woodland and Kohlmeier,
2009). Initial views of skin immune surveillance greatly empha-858 Immunity 35, December 23, 2011 ª2011 Elsevier Inc.sized the role of circulatory memory cells, trafficking between
skin-draining LNs and skin, poised to react quickly to a
secondary challenge (Kupper and Fuhlbrigge, 2004; Streilein,
1983). Effector T cells gain tissue-specific tropism by the DC-
imprinted expression of tissue-specific homing markers, deter-
mining and directing T cell migration to the tissue from which
the cognate antigen is originally derived. For instance, imprinting
for intestinal migration results in the expression of the gut-
homing markers a4b7 and CCR9, whereas the a1b1 integrin
very late antigen-1 (VLA-1) is involved in T cell migration to the
lung. Expression of cutaneous leukocyte antigen (CLA), CCR4,
and CCR10 determines T cell cutaneous tropism (Sheridan and
Lefranc¸ois, 2011). It has been suggested that skin DCs can
metabolize vitamin D3 to 1,25(OH)2D3 through which they
‘‘imprint’’ T cells with a skin-homing signature via upregulation
of CCR10 (Sigmundsdottir et al., 2007).
There is increasing evidence to support the concept of skin-
resident T cells, in keeping with other barrier sites such as the
lung and gut. The skin is thought to harbor a subset of Trm cells
that do not circulate but are strategically positioned in both
epidermis and dermis as the first-line defense in the tissue
(Boyman et al., 2007; Clark, 2010). It has been estimated that
the skin of a normal adult individual contains approximately
20 billion T cells, nearly twice the number present in the entire
circulation. More importantly, 98% of CLA+ skin-homing lym-
phocytes in the body reside in the skin under physiological
conditions (Clark et al., 2006). Our own model of T cell-mediated
skin inflammation strongly implies the existence of a Trm cell
compartment with a critical functional role, because upon xeno-
transplantion of human nonlesional psoriatic skin onto immuno-
deficient mice, fully fledged psoriatic lesions develop in the
absence of T cell recruitment from blood (Boyman et al., 2004).
Development of skin inflammation depends on the ability of
locally activated skin Trm cells, present in the initial graft, to
migrate into the epidermis via VLA-1 binding to collagen IV (Con-
rad et al., 2007). Elegant studies of herpes simplex virus (HSV)
skin infection clearly implicate Trm cells in long-term peripheral
immunity (Gebhardt et al., 2009;Wakim et al., 2008), as indicated
by the fact that HSV-1-specific CD8+ Trm cells are retained in
latently infected ganglia and are able to proliferate in situ and
to contain virus reactivation with CD4+ Trm cell help (Wakim
et al., 2008). HSV-1-specific CD8+ skin Trm cells expressing
CD103 and VLA-1 are also retained in healed skin where they
promote long-lasting and effective protection against local
reinfection (Gebhardt et al., 2009).
Important differences between CD4+ and CD8+ T cell subsets
in terms of tissue localization and migratory capacity have also
been highlighted (Gebhardt et al., 2011). Once infection has
resolved and immunological memory has taken place, memory
CD8+ T cells remain sequestered in the epidermis, in close prox-
imity to the original infection site. In contrast, memory CD4+
T cells rapidly traffic through the dermis, re-enter the circulation,
and rapidly reach previously uninvolved skin in the case of
secondary infection (Gebhardt et al., 2011). Therefore, the well-
known division of labor between helper CD4+ and cytotoxic
CD8+ T cells seems to also include a spatial compartmentaliza-
tion. Besides these animal models, the existence of a popula-
tion of virus-specific T cells that increases in number during
subclinical HSV reactivation has been documented in humans
Figure 1. Tissue-Resident Memory T Cells Provide Long-Term Peripheral Immunity in Human Skin
After first skin infection (left) with a pathogen, dermal dendritic cells (DDCs) take up foreign antigens (Ags) and present them to naive T cells in the skin-draining
lymph node, initiating an adaptive immune response. Ag-specific central memory T (Tcm) cells, expressing CCR7 andCD62L andmainly residing in lymph nodes,
and effector memory T (Tem) cells, expressing cutaneous leukocyte antigen (CLA), CCR4, and CCR10, are generated. Tem cells migrate to sites of skin infection
and remain there after the pathogen has been cleared to become tissue-resident memory T (Trm) cells. Upon second encounter with the same Ag (right), DDCs
present Ag in situ to skin Trm cells, allowing a quick response to local reinfection. Moreover, DDCs present Ag to Tcm cells in skin-draining lymph nodes, giving
rise to another population of Tem cells that migrate into skin and contribute to clearance of infection.
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the different migration pattern of CD4+ and CD8+ T cells holds
true for tissues other than skin and most importantly whether
this can be exploited for therapeutic application.
Skin Immune Network Ensures Host Defense and Tissue
Repair against Chemical and Physical Insults
Having discussed the skin as an immune-competent organ,
capable of rapid response to danger, we will now explore the
vast array of signals that can trigger this response. Damaging
the skin physical barrier may have severe detrimental effects
on deeper body tissues, and therefore, the skin reacts to
exposure to chemicals and to physical trauma by mounting
a robust inflammatory response that prevents further damage
and ultimately attempts to restore tissue function.
Exposure to irritant xenobiotic compounds triggers the activa-
tion of the skin innate immune system and results in the skin
inflammatory condition known as irritant contact dermatitis(ICD). This nonspecific inflammatory reaction is characterized
by an abundance of KC-derived proinflammatory mediators,
neutrophil and macrophage infiltrate, and KC apoptosis and/or
necrosis followed by compensatory proliferation (Nosbaum
et al., 2009). ICD is usually self-limiting and spontaneously re-
solves, but in some individuals the contact irritant can act as a
hapten, resulting in an allergic contact dermatitis (ACD) (dis-
cussed later).
The primary immunological task of the skin is to maintain body
homeostasis and is most evident in the physiologic process of
wound healing after tissue injury. Wound healing occurs in three
sequential stages: inflammation, new tissue formation, and
tissue remodeling. Within seconds of the injury, a well-orches-
trated cascade of inflammatory events take place. Exposed
collagen activates the coagulation cascade leading to an initial
platelet plug, which is sealed and solidified by fibrin, and even-
tually leads to a blood clot at the skin surface, which prevents
further loss of blood and fluid and serves as a scaffold forImmunity 35, December 23, 2011 ª2011 Elsevier Inc. 859
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wounding and launch the immune response. Although they
may be dispensable for proper tissue repair, in animal models
of artificial and sterile wounds (Martin and Leibovich, 2005),
they kill bacteria and produce chemokines, cytokines, and
proteolytic enzymes that encourage monocyte, pDC, and
lymphocyte recruitment and activation (Nathan, 2006). Two
days after injury, neutrophils are outnumbered by incoming
monocyte-derived macrophages. In mice, two distinct mono-
cyte subpopulations have been described (Auffray et al., 2009)
as giving rise to wound macrophages with different kinetics
(Brancato and Albina, 2011). Inflammatory monocytes, charac-
terized as Ly6ChiCCR2hiCX3CR1lo, migrate into sites of inflam-
mation, early after injury, to produce proinflammatory cytokines
and clear wound debris by phagocytosis. A second population,
defined as Ly6CloCCR2loCX3CR1hi, egresses from the circula-
tion later and produces transforming growth factor-b (TGF-b)
and vascular endothelial growth factor (VEGF). In humans,
CD16+ cells highly expressing CX3CR1 are considered the
ortholog of Ly6CloCCR2loCX3CR1hi murine monocytes, whereas
CD16CCR2+CX3CR1lo monocytes resemble Ly6ChiCCR2hi
CX3CR1lo murine monocytes (Auffray et al., 2009). That macro-
phages undergo temporal evolution as the wound matures is
supported by a recent study uncovering their rather complex
phenotype, sharing traits associated with both alternative and
classical activation (Daley et al., 2010). In contrast to an early
mouse model of macrophage deficiency suggesting a detri-
mental role for macrophages in promoting scar formation (Martin
and Leibovich, 2005), three recent reports (Goren et al., 2009;
Lucas et al., 2010; Mirza et al., 2009) depleting monocytes and
macrophages during wound healing strongly confirm their
essential role as main orchestrator of the tissue repair. Macro-
phage depletion results in delayed re-epithelialization and im-
paired angiogenesis, associated with increased expression of
inflammatory mediators and reduced expression of VEGF and
TGF-b1. Thus, it is likely that macrophages modulate wound
closure and dermal healing, in part by regulating the cytokine
environment of the healing wound. Nonetheless, their role is
probably multifaceted and further studies are required to under-
stand their contribution to the different stages of the healing
process.
Other leukocytes to enter the wounded area in the inflam-
matory stages include plasmacytoid DCs (pDCs). pDCs are a
unique subset of DCs, normally absent in skin and characterized
by extraordinary secretion of type I interferons (IFNs) via toll-like
receptor-7 (TLR7)- and TLR9-dependent recognition of nucleic
acids (Conrad et al., 2009). Two studies on a murine model of
tape stripping-induced mechanical skin injury have recently
uncovered a previously unappreciated role for pDCs in wound
healing. pDCs were found to infiltrate skin wounds as early as
neutrophils and to react to self nucleic acids released by dying
cells as a result of coupling with the cathelicidin LL37, and
thereby inducing the typical type I IFN gene signature (Gregorio
et al., 2010; Guiducci et al., 2010). pDCs also contribute to
the early inflammatory responses and the re-epithelization of
injured wound by releasing IL-6 and promoting the production
of IL-17A and IL-22 by T cells. Of interest, a similar course of
events after skin injury also occurs in humans (Gregorio et al.,
2010).860 Immunity 35, December 23, 2011 ª2011 Elsevier Inc.Skin-resident T cells residing in the epidermis have a crucial
role in promoting wound healing. In mice, Vg5Vd1 DETCs act
as fast, early responders to skin damage promoting tissue repair
(Havran and Jameson, 2010). After wounding, DETCs respond to
an as-yet-unknown antigen, expressed on damaged or stressed
KCs, by proliferating and producing proinflammatory cytokines,
chemokines, and KC growth factors. DETCs are critical in skin
repair as shown by the fact that mice lacking DETCs exhibit
a delay in wound closure. DETCs also modulate conventional
ab T cell and macrophage recruitment to the skin by enhancing
the deposition of extracellular matrix (ECM) molecules (Havran
and Jameson, 2010). As mentioned earlier, DETCs are not
present in humans and gd T cells are rare in normal healthy
skin, representing about 2%–9% of dermal and 1%–10% of
epidermal T cells. It has long been speculated whether or not
humans have a population of epidermal T cells capable of aiding
in wound healing. Toulon et al. (2009) have recently reported that
in humans, both ab ‘‘conventional’’ and Vd1 ‘‘unconventional’’
epidermal T cells are able to produce insulin-like growth
factor-1 (IGF-1) upon activation and to promote wound healing
in a skin organ culture model. Epidermal T cells isolated from
patients with chronic wounds are refractory to stimulation and
do not produce IGF-1. Moreover, we have recently shown that
a population of skin-homing Vg9Vd2-expressing T cells, able to
produce the same spectrum of mediators, is rapidly attracted
into perturbed skin (Laggner et al., 2011). Thus, both recruited
and skin-resident human gd T cells act as early effector sentinels
upon trauma.
Among T cell-derived mediators involved in wound healing, a
prominent position is occupied by IL-22, in keeping with a similar
homeostatic role at other barrier surfaces, such as lung and gut
(Sonnenberg et al., 2011). An increasingly expanding variety of
adaptive (Th1, Th17, Tc17, ‘‘Th22,’’ and ‘‘Tc22’’) and innate-
like (LTi-like, gd T, NK, NKT) cell types have been reported to
produce IL-22 (Sonnenberg et al., 2011). To date only Th1,
Th17, and the recently described skin-homing IL-22-producing
‘‘Th22’’ cells (Duhen et al., 2009; Eyerich et al., 2009; Trifari
et al., 2009) have been reported to produce IL-22 in inflamed
human skin (Eyerich et al., 2009). Although named after their
signature cytokine, these IL-22-producing cells still lack the
attribution of a master regulator transcription factor to be for-
mally recognized as a distinct T helper cell lineage. The aryl
hydrocarbon receptor (AHR), involved in Th17 cell differentiation
(Stockinger et al., 2011) and recently shown to be an essential
regulator of murine DETCs and intraepithelial lymphocytes in
the gut (Kadow et al., 2011; Li et al., 2011), has been suggested
as the putative master regulator, but this has not been con-
clusively proven as yet. Nevertheless, we will henceforth refer
to them as Th22 cells.
IL-22 exerts its effects only on epithelial cells, in keeping with
the expression pattern of the IL-22R complex (Wolk et al., 2004).
The early identification of genes selectively regulated by IL-22
in KCs reveal its involvement in tissue repair (Boniface et al.,
2005). Regulated genes include those coding for keratinocyte
differentiation-associated protein, mobility and migration-regu-
lating proteins, and AMPs.More recently, transcriptome profiling
of Th22 clones shows selective expression of growth factors
(FGFs) and chemokines involved in tissue remodeling, angiogen-
esis, and fibrosis (Eyerich et al., 2009). Supernatants from Th22
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(CXCL9, CXCL10, and CXCL11), T cell growth factors (IL-7 and
IL-15), and AMPs and to enhance wound healing in vitro. Hence,
IL-22 functions promote the formation of new tissue in the
second stage of the wound healing process. This stage occurs
2–10 days after injury and is characterized by proliferation and
migration of different cell types. KCs migrate over the injured
dermis, proliferate in response to growth factors produced by
gd T cells, and terminally differentiate in response to IL-22 to ulti-
mately restore the barrier function of the epithelium. At 2–3weeks
after injury, the majority of the inflammatory cells undergoes
apoptosis or exit from the wound, and fibroblasts become the
key players. Fibroblast-derived ECM, mainly collagen, forms
the bulk of the mature scar while differentiated myofibroblasts
bring the edges of the wound together. Increased angiogenesis
is also a prominent feature promoting fibroblast activity and scar
formation. The remodeling phase, a stage lasting up to 2 years
and involving reorganization of collagen fibers, terminates the
healing process with the wound progressively contracting near
its surface. Such a controlled and tightly regulated cascade of
events ultimately results in an uncomplicated fine scar with little
fibrosis and the return to near-normal tissue architecture.
However, if these events are not controlled and occur out of
sequence, the wound does not heal, resulting in chronic wounds
(such as in diabetic patients), which can be accompanied by
excessive fibrosis, resulting in an impaired skin structure and
thus compromising its functional integrity.
Skin Provides First Line Defense against Pathogens
Keratinocytes can be considered the first immune sentinels
encountered by pathogens and they need to be quick and effi-
cient in sensing and responding to danger (Nestle et al., 2009a).
On first encountering a microbe, KCs are alerted to potential
danger by recognizing conserved microbial structures known
as pathogen-associated molecular patterns (PAMPs) via their
pattern recognition receptors (PRRs) (Takeuchi and Akira,
2010). One major group of PRRs are Toll-like receptors (TLRs),
which keratinocytes express on their surface (TLR-1, TLR-2,
TLR-4, TLR-5, and TLR-6) and in their endosomes (TLR-3 and
TLR-9). TLR engagement triggers activation of nuclear factor-
kappa B (NF-kB) and interferon regulatory factor (IRF), which in
turn induces immune and inflammatory genes, namely, tumor
necrosis factor (TNF) and type I IFNs.
Another way in which KCs try to curtail the immediate micro-
bial threat is by releasing an abundant supply of proinflammatory
cytokines as a result of activating a large multiprotein oligomer
complex, within the cytoplasm, called the inflammasome (Feld-
meyer et al., 2010). This in turn activates the enzyme caspase 1,
which cleaves unprocessed pro-interleukin-1b (pro-IL-1b) and
pro-IL-18, stored in KCs, into the active IL-1b and IL-18. Acti-
vated keratinocytes release processed IL-1 (Dombrowski et al.,
2011), enabling neighboring epithelial cells to respond by ampli-
fying the signal through further production of IL-1a, in addition to
IL-1b, TNF, and IL-6.
Another critical role fulfilled by KCs in the defense against
invading microorganisms is the induction of numerous AMPs.
There are many cationic AMPs, such as the cathelicidin
(LL-37), defensins, and S100 family proteins (Harder and
Schro¨der, 2005). These cationic molecules destroy bacteria bycreating holes in their anionically charged cell walls or by
sequestrating iron required for bacterial growth (Gla¨ser et al.,
2005). Proinflammatory cytokines (IL-1a, IL-1b, IFN-g, TNF) dif-
ferentially regulate the expression of genes encoding for a
number of AMPs, and IL-17A, IL-17F, and IL-22 are potent
inducers of AMPs (Sonnenberg et al., 2011).
The important role that AMPs play in the cutaneous defense
against infection is apparent in patients with AD, who are highly
susceptible to cutaneous bacterial and viral infections as a result
of decreased amounts of b-defensins and cathelicidins (Ong
et al., 2002), whereas skin infections are not common to a dis-
ease like psoriasis associated with increased production of
AMPs. Overall, the general increase in cytokines and chemo-
kines, such as CXCL9, CXCL10, CXCL11, CCL27, and CCL20,
resulting from activated KCs (Albanesi et al., 2001) leads to an
increase in the neutrophil and macrophage infiltrate in addition
to T lymphocyte recruitment.
As mentioned earlier, pDCs are normally absent in peripheral
nonlymphoid organs but migrate to the skin after viral infections.
pDCs produce large quantities of type I IFNs that limit the spread
of viral infections and induce maturation and activation of DCs,
thereby promoting cell-mediated protective immunity (Conrad
et al., 2009). Upon activation, pDCs lose their plasmacytoid
morphology and the ability to produce type I IFNs and differen-
tiate into cells with a dendritic morphology expressing major
histocompatibility complex (MHC) and T cell costimulatorymole-
cules. However, even in their mature status, pDCs are less effi-
cient than DCs in antigen presentation, especially in priming
naive T cells, and most probably do not have cross-presentation
capacity. Nevertheless, pDCs sustain protective responses at
sites of infection and display functional plasticity in promoting
almost every type of effector T helper subsets in vitro, including
differentiation of skin-homing Th22 cells, via IL-6 and TNF
(Duhen et al., 2009).
Initiation of adaptive immune responses against pathogens
that gain access to the skin requires pathogen-derived antigen
capture, processing, and presentation by DCs followed by
DC-mediated priming of naive T cells. Epidermal LCs extending
dendritic processes to the stratum corneum have traditionally
been regarded as the typical peripheral DCs patrolling the cuta-
neous barrier (Schuler and Steinman, 1985). LCs are in an imma-
ture state, yet well equipped with a series of innate receptors to
sample the environment. PAMPs trigger migration toward skin
draining lymph nodes where LCs acquire a mature phenotype
and the functional ability to present antigens to naive T cells.
However, this view, known as the ‘‘LC paradigm,’’ has been
challenged by a number of murine studies that have led to
a re-evaluation of the role of LCs in pathogen-induced immune
responses (Kaplan, 2010; Merad et al., 2008; Romani et al.,
2010). Recently identified murine CD207+CD103+ DDCs (Bursch
et al., 2007; Ginhoux et al., 2007; Poulin et al., 2007) have been
shown to perform some of the tasks previously attributed to
LCs, such as cross-presentation (Bedoui et al., 2009; Henri
et al., 2010), despite other studies having shown cross-presen-
tation by LCs in vitro and ex vivo (Flacher et al., 2010; Klechevsky
et al., 2008). Recently, two studies shed some light on the role of
LCs in adaptive immunity (Bennett et al., 2011; Igya´rto´ et al.,
2011). By using a TLR agonist-induced graft versus host disease
(GvHD) model, Bennett et al. (2011) showed that LCs are notImmunity 35, December 23, 2011 ª2011 Elsevier Inc. 861
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cytotoxic responses. Finally, Igya´rto´ et al. (2011) have investi-
gated LC function in a skin model of recombinant Candida
albicans infection. Confirming previous findings, they have found
that CD207+CD103+ DDCs, but not LCs, are necessary and suffi-
cient for cross-presentation of exogenous antigen to CD8+
T cells in vivo. However, direct antigen presentation by LCs is
required for Th17 cell differentiation promoted by LC-derived
IL-6, IL-1b, and IL-23. Taken together these two studies suggest
that LCs do play a specific and nonredundant role in antigen-
specific responses.
Previously overlooked on the assumption that all CD207+ DCs
found in the dermis were LCs en route to draining LNs, CD207+
CD103+ DDCs have raised considerable interest since their iden-
tification (Kaplan, 2010). They have been consistently identified
in mice as the only skin-derived DC subset able to cross-present
viral antigens and self-protein expressed by keratinocytes in
both in vitro and in vivo settings (Bedoui et al., 2009; Henri
et al., 2010). Moreover, CD207+ DDCs promote antigen-specific
cytotoxic T lymphocytes (CTL) and Th1 cells while inhibiting LCs
and CD207 DDC-induced Th17 cells (Igya´rto´ et al., 2011).
Counterparts of CD207+CD103+ DDCs are also found residing
at other mucosal sites, including the lung and small intestine
(Heath andCarbone, 2009), further supporting a putative sentinel
role at barrier surfaces. Despite the growing number of murine
DC subsets identified to date, CD207+CD103+ DDCs share
their cross-presenting capability only with splenic CD8a DCs.
Because both cell subsets depend on the transcription factor
Batf3 for their development, similar ontogeny and functions for
these subsets can be hypothesized. No human equivalent of
dermal CD207+CD103+ DDCs has been identified so far. Human
CD207+ DDCs are scarce, representing less than 5% of DDCs in
human skin (Chu et al., 2011; Romani et al., 2010), and whether
they correspond to the CD207+CD103+ DDCs described in mice
remains to be investigated.
An additional subset of dermal DCs involved in building immu-
nity to infection is a population of monocyte-derived DDCs
(mo-DDCs) that patrol the skin during inflammation. They are
important for adequate immune response against pathogens,
e.g., inducing protective Th1 cell responses against Leishmania
major (Leo´n et al., 2007). Interestingly, inflammatory mo-DDCs
and DDCs found in steady state display similar phenotypic
features, hinting to a monocytic origin for DDCs (Lo´pez-Bravo
and Ardavı´n, 2008). A formal identification of inflammatory
mo-DCs during infection in human is still lacking. A population
of ‘‘inflammatory DDCs,’’ characterized as CD11c+CD1c, has
been identified in inflamed psoriatic lesions (Zaba et al., 2009b)
and is believed to be the equivalent to mouse splenic TNF-
and inducible nitric oxide synthase (iNOS)-producing DCs
(TIP-DCs) found in infection models.
After presentation of the cognate antigen by DCs and accord-
ing to the surrounding cytokine milieu, naive T cells differentiate
into effector cells endowed with critical effector functions, such
as cytokine production and cytotoxicity. All CD4+ Th cell lineages
identified to date contribute to provide protective cutaneous
immunity against a range of intracellular and extracellular patho-
gens. Cytotoxic CD8+ T cells, producing type 1, 2, and 17 cyto-
kines, also occur. Among CD4+ T cells, Th17 cells perform an
essential first-line defense against a number of fungal and bacte-862 Immunity 35, December 23, 2011 ª2011 Elsevier Inc.rial skin infections (Miossec et al., 2009). Mice lacking IL-23 show
impaired Th17 cell response to Candida albicans infection
(Kagami et al., 2010). In humans, genetic defects in a variety
of Th17 cell-related genes, such as those coding IL-12p40,
IL-12Rb1, STAT-3, IL-17RA, and IL-17F, cause severe immuno-
deficiency and dramatic susceptibility to and recurrence of
bacterial and fungal infections, as seen in Job’s syndrome and
chronic mucocutaneous candidiasis (de Beaucoudrey et al.,
2008; Puel et al., 2011), respectively. Lack of Th17 cytokines
observed in these patients is likely to impair recruitment of
neutrophils, activation of macrophages, and production of
AMPs by KCs and neutrophils, thus interrupting the crosstalk
between adaptive and innate immunity required for full pathogen
clearance. Other important sources of IL-17A at barrier sites
come from innate immune cells and unconventional T cells
(Cua and Tato, 2010). In the lung, gd T cells have been identified
as important IL-17A producers inmice and patients infected with
tuberculosis (Cua and Tato, 2010). In the skin DETCs (Cho et al.,
2010), a recently identified dermal-resident gd T cell subset (Cai
et al., 2011; Gray et al., 2011; Sumaria et al., 2011) as well as
skin-homing Vg9Vd2 T cells (Laggner et al., 2011) produce IL-
17A. As to which is the primary source probably depends on
the triggering pathogen. Dermal gd T cells are motile, able to
proliferate in situ and orchestrate the immune surveillance
program by recruiting neutrophils and promoting CD4+ T cell
expansion (Sumaria et al., 2011), and thus link innate and adap-
tive immunity.Skin as the Site for Immune-Mediated Inflammatory
Pathologies
A critical task for skin is to ensure that active defense and tolero-
genic and/or regulatory mechanisms are in place to maintain the
homeostatic balance between appropriate beneficial immune
response and unnecessary immune responses to self-antigens,
harmless microorganisms, and environmental chemicals.
Skin DCs and regulatory T (Treg) cells play a critical role in
orchestrating extrinsic mechanisms of peripheral tolerance.
Murine CD207+CD103+ DDCs are able to mediate T cell toler-
ance, possibly in the context of their cross-presentation (or
rather ‘‘cross-tolerance’’) capability by which they present exog-
enous self-antigens in the steady state to induce unresponsive-
ness of self-reactive CD8+ T cells (Lutz and Kurts, 2009). In
humans, the majority of circulatory CD4+CD25hiFoxp3+ Treg
cells bear skin-homing receptors (Hirahara et al., 2006) and
make up 10% of the resident T cells in normal skin. Accordingly,
lack of skin-homing molecules CD103, CCR4, and P- and E-se-
lectin ligands severely affects the migration and/or retention of
Treg cells within the skin and results in impaired pathogen
clearance and skin-specific autoimmunity (Campbell and
Koch, 2011). Moreover, Treg cells prevent unnecessary immune
responses to harmless antigens applied onto the skin and control
the magnitude of the inflammatory reaction (Cavani, 2008).
A break of self-tolerance and failure of regulatory mechanisms
may contribute to the development of immune-mediated in-
flammatory skin diseases such as ACD and psoriasis. Special
emphasis will be given to psoriasis because of the recent prog-
ressmade in understanding its complex pathogenesis as a result
of the success of targeted biologic therapies.
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ACD is a typical delayed-type hypersensitivity (DTH) reaction to
a sensitizer agent, characterized by two distinct phases. The
sensitization, or induction, phase occurs at the first contact of
skin with a strong hapten able to form complexes with host
proteins and trigger activation of the innate immune system,
similar to ICD. However, in ACD this leads to the generation of
hapten-specific T cells in LNs and their migration back to the
skin. Re-exposure of sensitized individuals with the same hapten
results in the elicitation phase of ACD. Hapten-specific T cells
are activated in skin and mediate adaptive immunity responsible
for the cutaneous lesions. This inflammatory reaction persists for
only a few days and rapidly resolves thanks to downregulatory
mechanisms. Because only a minority of exposed individuals
develop ACD, genetic predisposition is likely to play a role;
however, data so far are inconclusive and genome-wide associ-
ation studies (GWASs) are still not available. TLRs and the inflam-
masome mediate the initial innate inflammation in murine
contact hypersensitivity (CHS) (Martin et al., 2011), the experi-
mental model of ACD, with TLR4 identified as the receptor for
nickel in a recent study (Schmidt et al., 2010). Identification of
which skin DC subset is responsible for initiating the hapten-
induced adaptive response has been the subject of extensive
work (Kaplan, 2010; Romani et al., 2010). In keeping with the
‘‘LC paradigm,’’ epidermal LCs are traditionally considered the
initiators of CHS. This concept was first challenged by classical
depletion experiments, showing enhanced CHS in the absence
of LCs (Grabbe et al., 1995). Later, inducible or constitutive LC
ablation in transgenic mice did not abrogate but rather resulted
in CHS of similar (Kissenpfennig et al., 2005) or even enhanced
(Kaplan et al., 2005) magnitude, depending on the ablation
strategy used. Finally, CD207+CD103+ DDCs are found to induce
CHS reactions in vivo and to compensate for LC absence
(Bursch et al., 2007). Recently, functional redundancy of LCs
and CD207+CD103+ DDCs has been proposed, depending on
hapten accessibility. In the presence of a high concentration of
hapten, which makes it accessible to both epidermal LCs and
CD207+CD103+ DDCs, the latter compensate for the absence
of LCs, although LCs are necessary to induce CHS in the pres-
ence of lower hapten doses (Honda et al., 2010; Noordegraaf
et al., 2010). However, mice lacking the transcription factor
Batf-3, and therefore lacking CD103+CD11b DCs in skin,
develop a normal CHS response (Edelson et al., 2010). A tolero-
genic role for LCs in damping CHS reactions has also been
postulated with possible mechanisms involving interaction with
cognate T cells and production of IL-10 to inhibit expansion of
hapten-specific T effector cells (Igyarto et al., 2009; Kaplan,
2010). Therefore, further studies are required to address the rela-
tive contribution of different DC subsets to CHS.
Both CHSmodels and studies on nickel ACD individuals show
that hapten-specific CD8+ T cells are the main effector cells of
CHS with CD4+ T cells mainly playing a regulatory role. KC-
targeted cytotoxicity, enhanced by the combined release of
IFN-g and IL-17A (Pennino et al., 2010), is a key pathogenic
mechanism by which CD8+ T cells mediate disease. Resolution
of ACD relies on a number of regulatory mechanisms, including
apoptosis of effector T lymphocytes, release of immunosup-
pressive cytokines (IL-10 and TGF-b), and induction of Treg cells
(Cavani, 2008). Defective regulatory function of Treg cells corre-late with the development of ACD to nickel, suggesting their
critical role in dampening T cell activation at the site of hapten
application in allergic individuals.
Psoriasis
Psoriasis is a chronic immune-mediated inflammatory skin
disease characterized by highly inflamed and sharply demar-
cated scaly plaques (Nestle et al., 2009b). Histological features
consist of marked epidermal hyperplasia with dysregulated KC
differentiation, prominent inflammatory infiltrate, and increased
vascularization. A combination of environmental (streptococcal
pharyngitis, stress, skin trauma, and certain drugs) and genetic
(gene variants conferring disease susceptibility) factors trigger
the immuno-histological changes seen in the skin. Human
leukocyte antigen-C (HLA-C) within the MHC and at least 23
more genes, mainly belonging the IL-23-Th17 axis, the NF-kB
pathway, and the epidermal differentiation complex (EDC), are
identified to date as conferring susceptibility to psoriasis (Nair
et al., 2009; Strange et al., 2010). Researchers have long
debated whether psoriasis is an epidermal or an immune-
mediated disease, torn between the most prominent epidermal
changes and the unexpected efficacy of serendipitously admin-
istered immunosuppressive agents. Evidence, ranging from
the presence of clonally expanding T cells in the lesions to the
clinical benefit obtained with specific anti-T cell therapies to
humanizedmousemodels relying on T cells for disease develop-
ment, consistently points toward T cells as critical effectors.
Analogous to other autoimmune-mediated pathologies, psori-
asis has long been considered a Th1 cell-mediated disease.
However, insights from targeted therapies, combined with
genetic and experimental data, recently identify a critical role
for the IL-23-Th17 axis (Di Cesare et al., 2009). It is increasingly
more apparent that a pathogenic crosstalk between innate and
adaptive cells underpins the dysregulated immune response
leading to the aberrant epidermal proliferation.
The extraordinary success of biologic drugs targeting TNF as
well as IL-12 and IL-23 has dramatically changed patient care.
TNF-neutralizing agents used for psoriasis therapy are etaner-
cept, a human TNF receptor Fc fusion protein, and two TNF
monoclonal antibodies, infliximab and adalimumab. Cellular
and genomic analysis of etanercept-treated patients shows that
TNF blockade downregulates both innate and adaptive genes
(Gottlieb et al., 2005; Zaba et al., 2007). Patients rapidly downmo-
dulate innate cell-derived and Th17 cell-driving genes, such as
IL12B, IL23A, and IL1B as well as Th17 cytokines. Th1 cytokines
arealso reducedbut late indisease resolution (Zabaet al., 2009c).
Ustekinumab, a fully human monoclonal antibody directed
against the common p40 subunit shared by IL-12 and IL-23, is
also highly effective in psoriasis, showing superior efficacy to
anti-TNF therapy in a head-to-head trial (Griffiths et al., 2010).
Insights gleaned from clinical studies confirm genetic and
experimental data. We and others have shown, by GWAS, that
several genes of the IL-23 pathway, including IL23R, IL12B,
and IL23A, are associated with psoriasis (Capon et al., 2007;
Cargill et al., 2007; Nair et al., 2009). Moreover, we and others
have recently provided a functional explanation of how the
psoriasis-associated IL23R R381Q gene variant confers pro-
tection against Th17 cell-mediated immuno-pathologies by
impairing IL-23-induced Th17 cell responses (Di Meglio et al.,Immunity 35, December 23, 2011 ª2011 Elsevier Inc. 863
Figure 2. Immunopathogenesis of Psoriasis
The combination of environmental factors with psoriasis-susceptibility genes triggers an orchestrated cascade of pathogenic events leading to disease initiation
and plaque formation. In the initiation phase, proinflammatory crosstalk between injured or stressed keratinocytes (KCs), releasing self-nucleic acids and LL-37,
recruited plasmacytoid dendritic cells (pDCs) producing IFN-a, activated dermal DCs (DDCs), and inflammatory DDCs (iDDCs), the latter producing IL-23, TNF,
and nitric oxide radicals (NO$), promoting the activation of skin-resident and newly recruited T cells that lead to plaque formation. IL-23 stimulates T helper 17
(Th17) and T cytotoxic 17 (Tc17) cells, expressing cutaneous leukocyte antigen (CLA), CCR6, and CCR4, plus very late antigen-1 (VLA-1) in the epidermis, to
release IL-17A, IL-17F, IL-22, and IFN-g. IFN-g further activates DDCs. IL-17A and IL-17F acts on KCs promoting production of T cells and neutrophil-attracting
chemokines (CXCL1,3,8-11;CCL17-20) and antimicrobial peptides (AMPs): S100 proteins and LL-37. CCL20 favors the recruitment of more Th17 cells. IL-22,
also produced by Th1 cells, expressing CXCR3 and skin-homing marker CLA, and Th22 and Tc22 cells, expressing CCR6, CCR10, and CLA, induces epidermal
hyperplasia by impairing KC terminal differentiation. Recruited unconventional Vg9Vd2 T cells, expressing CLA and CCR6, are activated by pDCs-derived IFN-a
and release further proinflammatory cytokines (IL-17A, IFN-g, TNF) as well as neutrophils (Neut) and Th1 cell-attracting chemokines (CCL3-5). Infiltrating Neut,
mast cells, and macrophages (M) contribute to the proinflammatory environment producing cytokines (IL-17A, TNF), AMPs (S100 proteins, LL-37), and che-
mokines. Crosstalk between keratinocytes producing IL-1, TNF and transforming growth factor beta (TGF-b), and fibroblasts, which in turn release keratinocyte
growth factor (KGF), epidermal growth factor (EGF), and TGF-b, and possibly Th22 cells releasing fibroblast growth factor (FGFs), contribute to tissue reorga-
nization.
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amounts of IL-23 (Lee et al., 2004) and IL-23R (Tonel et al.,
2010;Wilson et al., 2007), essential for Th17 cell effector function
and pathogenicity, as well as Th17 cytokines (Wilson et al.,
2007), are detected in psoriatic skin. Both IL-23 and Th17 cyto-
kines are downregulated after therapies (Gottlieb et al., 2005).
Th17 cells and IL-17A and IFN-g or IL-17A and IL-22 double-
producing cells are also described in psoriasis patients (Eyerich
et al., 2009; Lowes et al., 2008). Moreover, IL-23 induces psori-
asis-like skin inflammation in murine models (Chan et al., 2006;
Zheng et al., 2007). Most importantly, we have recently shown864 Immunity 35, December 23, 2011 ª2011 Elsevier Inc.in our xenotransplantation psoriasis model that selective target-
ing of IL-23 alone is as effective as anti-TNF blockade (Tonel
et al., 2010), strongly suggesting that the beneficial effect of us-
tekinumab is due to its activity on IL-23 and not IL-12. Phase I/IIa
clinical trial results for secukinimab (Hueber et al., 2010), an IL-17
monoclonal Ab, further support the beneficial effects of targeting
the Th17 cell axis in psoriasis.
In the psoriasis model depicted in Figure 2, we integrate
known environmental and genetic factors triggering the disease
with established cellular and molecular effectors reported to
contribute to psoriasis pathogenesis.
Figure 3. A Psoriasis Interactome
Gene expression data pooled from large patient samples can be used to
generate a disease interactome. An interactome is a network of inter-
connected genes based on similar expression profiles across tissues. Differ-
entially expressed genes between normal and psoriatic skin are shown as
a heatmap. A coexpression interactome is created where nodes reflect genes
and edges the degree of coexpression. This psoriatic interactome can be used
as a disease-relevant molecular reference data set, against which differentially
expressed gene transcripts generated from experimental models are
assessed.
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predisposed individuals, carrying susceptibility psoriasis alleles,
triggers disease development (Nestle et al., 2009b). In the initia-
tion phase, LL-37 released by KCs, after trauma or infection,
binds to self-DNA and self-RNA fragments (Ganguly et al.,
2009; Lande et al., 2007) released by stressed or dying skin cells.
These complexes of LL-37 and self-DNA activate pDCs to
produce IFN-a (Lande et al., 2007). Keratinocyte-derived IL-1b,
IL-6, TNF, pDC-derived IFN-a, and self-RNA-LL-37 complexes
can all activate DDCs. DDCs migrate to the skin-draining LNs
to present as-yet-unknown antigen (either of self or of microbial
origin) to naive T cells and promote their differentiation into Th17
and Tc17 cells (Zaba et al., 2009a) as well as Th1 and Th22 cells.
Skin-homing Th17 and Tc17 cells, expressing CLA, CCR4, and
CCR6, migrate via lymphatic and blood vessels into psoriatic
dermis, attracted by keratinocyte-derived CCL20 and CCL17.
Moreover, inflammatory DCs produce IL-23A, nitric oxide (NO)
radicals, and TNF (Zaba et al., 2009a). IL-23A activates recruited
and skin-resident Th17 and Tc17 cells to release IL-17A and
IL-17F but also IL-22 and IFN-g. IL-17A and IL-17F stimulate
KCs to produce neutrophil-recruiting chemokines and AMPs,
including LL-37 and S100 family members (Wilson et al., 2007).
Neutrophils infiltrating the epidermis and mast cells mainly in
the dermis produce more proinflammatory mediators, including
IL-17A (Lin et al., 2011), thereby contributing to the proinflamma-
tory environment. S100A7 and S100A15 are chemoattactant for
leucocytes promoting both Th1 and Th17 cell response (Wolf
et al., 2010). VLA-1-expressing cytotoxic CD8+ T cells accumu-
late in the epidermis (Conrad et al., 2007) and also produce
IL-17A. Unconventional Vg9Vd2 T cells are recruited into the
lesions via CCL20, possibly contributing to the proinflammatory
milieu by releasing AMPs, IL-17A, IFN-g, and TNF as well as
neutrophils and Th1 cell-attracting chemokines (Laggner et al.,
2011). Th1 cells and Th22 cells also infiltrate the lesion, attracted
by KC-derived chemokines and/or activated in situ by the proin-
flammatory milieu. Finally, IL-22, potentially produced by Th1,
Th17, and Th22 cells in the lesion (Eyerich et al., 2009), induces
epidermal hyperplasia (Ma et al., 2008; Zheng et al., 2007) by
impairing KC differentiation, with a possible contribution from
IL-17A. This orchestrated cascade of pathogenic events ulti-
mately leads to the formation of a psoriatic plaque characterized
by acanthosis (thickening of the skin), papillomatosis (elongation
of the epidermis into the papillary dermis), hypogranulosis (loss
of the stratum granulosum), and parakeratosis (retention of the
nucleus in the stratum corneum).
Despite knowing this sequence of events, at least 20% of
patients do not respond to anti-TNF and anti-IL-12+anti-IL-23
therapy, meaning that key pathogenic mechanisms are still ill
understood and the known mechanisms may not always apply
to every individual. As GWASs identify more psoriasis-suscepti-
bility genes, the next big challenge is not only their functional vali-
dation but also linkage to the environment. Finding the causative
link between genetic susceptibility and environmental factors
that trigger the aberrant immune response could provide addi-
tional therapeutic targets and might eventually deliver the
promise of personalized medicine.
Another useful approach to unravel the immune mechanisms
underlying psoriasis pathogenesis is to make use of systems
immunology. This involves integrating small in vivo and in vitrodata sets with in silico predictive models (Valeyev et al., 2010),
as well as deconstructing large quantities of clinical and experi-
mental data into meaningful immunology (Benoist et al., 2006).
An example of the latter approach is our use of publically avail-
able data from the Genetic Association Information Network
(GAIN) (Nair et al., 2009) to build up amolecular network of psori-
asis, by comparing gene expression profiles from psoriasis
patients against profiles from healthy controls. A molecular
network, or skin interactome, has been created by looking at
differentially expressed genes, genes linked to each other by
similar expression profiles across samples, between patients
and controls (Figure 3). Such a network can be used as a refer-
ence data set against which in-vitro- and in-vivo-derived gene
expression profiles can be compared and may ultimately help
to elucidate disease mechanisms, drug targets, and potential
biomarkers of disease and therapeutic response (Baraba´si
et al., 2011).
Finally, both gene-to-environment linkage and interactome
studies could be of relevance to other immune-mediated inflam-
matory disorders at barrier sites, such as Crohn’s disease, owing
to shared genetic variants, immunological pathways, and thera-
peutic targets with psoriasis.
Conclusions and Perspectives
The skin’s exceptional accessibility makes it an ideal model
system to interrogate in order to answer fundamental questions
about host immunity. This, in combination with advances in
technology, has led to considerable interest in cutaneous
research over the past few years. Recent exciting findings
have contributed to the concept of the skin as a multitasking
immune organ involved in promoting health. The advantage of
hosting commensal bacteria is being unraveled along with theImmunity 35, December 23, 2011 ª2011 Elsevier Inc. 865
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Reviewcontribution that innate cells make toward the generation
of beneficial and pathogenic immune responses. The iden-
tification of several skin-resident cell subsets, each with unique
critical capabilities, expands the skin immune network and
subsequently its functions. Recent findings have already been
translated into therapeutic options in psoriasis and have
provided a useful framework to further expand upon with re-
gard to other barrier tissues. Finally we suggest the potential
of using an integrative systems analysis to combine human
data sets with experimental data sets from biological model
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